The 30th JFCR－ISCC
December 11-12, 2026
Tomizo Yoshida Memorial Auditorium
3-8-31, Ariake, Koto-ku, Tokyo, Japan
December 11
12:00-12:30
Committee meeting
Opening Remarks
12:50-13:00
Naoya Fujita (Cancer Chemotherapy Center, JFCR)
Opening Remarks
Session I: Metabolic regulation to improve immune micro-environment
13:00-13:40
Ping-Chi Ho (Ludwig Institute for Cancer Research at UNIL)
Can you remember, exhausted T cells?
13:40-14:10
Kenji Chamoto (Kyoto University)
Mitochondrial FAO prevents T cell exhaustion by reducing aldehyde
14:10-14:40
Shogo Kumagai (Cancer Precision Medicine Center, JFCR)
Revealing the metabolic basis of cancer immunotherapy resistance
14:40-14:50
Discussion
14:50-15:10
Coffee Break
Meet-the-Expert Session 1: From undruggable to druggable
15:10-16:00
Charles G. Drake (Johnson & Johnson Innovative Medicine)
JNJ-6143: A novel AR-targeted RIP-TAC for prostate cancer
16:00-16:10
Discussion
Poster Flash Talks
16:10-17:20
Ayane Nakamura (Cancer Chemotherapy Center, JFCR)
RK-582, a tankyrase inhibitor, potentiates immune checkpoint blockade by remodeling the tumor immune microenvironment
Mayuki Ueda (Chugai Pharmaceutical Co., Ltd.)
AUBE00: A novel cyclic peptide pan-KRAS inhibitor targeting KRAS-activated cancers including KRAS-mutant cancers and wild-type colorectal cancer
Hiroyoshi Tanaka (Okayama University)
Novel 3D cell culture model of the fibrotic barrier in pancreatic cancer for mechanistic analyses and target identification
Hiroaki Tanaka (Astellas Pharma Inc.)
TBD
Ryuji Tamaki (Eisai Co., Ltd.)
Cell-free DNA-based inference of the activities of 370 + transcription factors mirrors their activities in tumors
Naoki Shijubou (Sapporo Medical University)
The ΔNp63–IL-1α axis in immune responsiveness and immune escape in lung squamous cell carcinoma
Yoshihide Kakimoto (MSD K.K.)
CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML
Shandan (Kanazawa University Cancer Research Institute)
Endothelial expression of FJX1 drives angiogenic activity of lung ECs and promotes breast cancer cell stemness at the metastatic site
Marie Kawahara (Cancer Chemotherapy Center, JFCR)
TBD
Poster viewing and networking
17:20-18:50
December 12
Session II: Revolution for pancreatic cancer therapy
9:00-9:40
Ida Aronchik (Revolution Medicines, Inc.)
Targeting oncogenic RAS with tri-complex inhibitors: Translational insights and strategies to overcome resistance
9:40-10:20
Adam Crystal (Tango Therapeutics, Inc.)
TBD
10:20-10:50
Atsushi Enomoto (Nagoya University)
Targeting cancer-associated fibroblast heterogeneity to enhance drug delivery
10:50-11:00
Discussion
11:00-11:20
Coffee Break
Meet-the-Expert Session 2
11:20-12:00
Ryan Corcoran (Mass General Brigham Cancer Institute, MGH)
No longer undruggable: Advances in targeting RAS-driven cancers
12:00-12:10
Discussion
Luncheon Seminar
12:20-13:10
Shunsuke Kitajima (Cancer Precision Medicine Center, JFCR)
TBD
13:10-13:20
Break
Session III: Next-generation leadership session
13:20-13:50
Naofumi Uesaka (Institute of Science Tokyo)
Translating neural activity into oncogenic signaling in glioma
13:50-14:30
Israel Cañadas (Fox Chase Cancer Center)
When tumors act like viruses: Exploiting viral mimicry for cancer therapy
14:30-14:40
Discussion
14:40-15:00
Coffee Break
Session IV: Other targets and drugs
15:00-15:30
Akiko Kimura (Takeda Pharmaceutical Co., Ltd.)
Development of PD-1/IL-2α-bispecific fusion protein
15:30-16:00
Shinya Ishii (Chugai Pharmaceutical Co., Ltd.)
Beyond binding: Expanding therapeutic possibilities through antibody engineering
16:00-16:30
Toshiyoshi Fujiwara (Kagawa Rosai Hospital)
Multidisciplinary oncolytic virotherapy for esophageal cancer patients unfit for standard treatments
16:30-16:40
Discussion
Closing Remarks
16:40-16:50
Ryan Corcoran (Mass General Brigham Cancer Institute, MGH)
Closing Remarks